(Q58903567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

postmenopausal osteoporosis

7 November 2019

main subject

osteoporosis

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

davide gatti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

S Girardello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

V Braga

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

G James

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

S Adami

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 July 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

119-122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Adverse effects of bisphosphonates. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Updated data on proximal femur bone mineral levels of US adults

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Guidelines for diagnosis and management of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900291-X

7 January 2021

10.1016/S8756-3282(00)00291-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865218%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference